Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could smooth away neck bands

NCT ID NCT07210463

Symptom relief Sponsor: Merz Aesthetics GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether NT 201 (a botulinum toxin injection) can safely reduce the appearance of moderate to severe neck bands (platysma prominence) in adults. About 300 participants in Europe will receive either NT 201 or a placebo injection. The study measures improvement using a doctor's and participant's rating scale at two weeks after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NT 201 (incobotulinumtoxinA, a botulinum toxin type A injection)
What this could lead to
If it works, this could provide a safe and effective cosmetic treatment to reduce the appearance of prominent neck bands.
What could go wrong
This is a cosmetic trial, so the main risk is that the treatment may not improve neck band appearance more than placebo. Side effects like injection site reactions or muscle weakness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

300 people

The number who actually took part.

Started

Oct 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of four (medial and lateral, left and right) platysmal bands assessed at screening and baseline. * A score of Grade 3 ('moderate') or Grade 4 ('severe') on the MAPSD at maximum contraction by the investigator AND participant. Exclusion Criteria: * Hypersensitivity or a history of allergic reaction to botulinum toxin of any serotype or any of their formulation ingredients. * Any medical condition that may put the participant at increased risk with exposure to botulinum toxin of any serotype, or any disorders that might interfere with neuromuscular function. * Any serious disease or disorder that could interfere with the safe completion of treatment or with study outcome assessments, or compromise participant safety. * Botulinum toxin treatment in the face (below the lower orbital rim), jawline, or neck within the last seven months. * History of lower face surgery, neck or chest surgery, and aesthetic procedures in the past 12 months and/or orthodontic procedures in the past 6 months. * Planned surgery or aesthetic procedures to the lower face, neck, or chest during the study period. * Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study products).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acetylcholine release inhibitors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acetylcholine release inhibitors Botulinum toxins, type A Cholinergic agents Incobotulinumtoxina Membrane transport modulators Molecular mechanisms of pharmacological action Neuromuscular agents Neurotransmitter agents Peripheral nervous system agents Physiological effects of drugs

Contacts and locations

Locations

  • Merz Investigative Site

    Lyon, 69006, France

  • Merz Investigative Site

    Munich, Bavaria, 80539, Germany

  • Merz Investigative Site

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Merz Investigative Site

    Potsdam, Brandenburg, 14467, Germany

  • Merz Investigative Site

    Friedrichsdorf, Hesse, 61381, Germany

  • Merz Investigative Site

    Kassel, Hesse, 34117, Germany

  • Merz Investigative Site

    Bochum, North Rhine-Westphalia, 44793, Germany

  • Merz Investigative Site

    Düsseldorf, North Rhine-Westphalia, 40212, Germany

  • Merz Investigative Site

    Drensteinfurt, 48317, Germany

  • Merz Investigative Site

    Hamburg, 20146, Germany

  • Merz Investigative Site

    Hamburg, 29354, Germany

  • Merz Investigative Site

    Wuppertal, 42287, Germany

  • Merz Investigative Site

    Krakow, Lesser Poland Voivodeship, 30-002, Poland

  • Merz Investigative Site

    Oświęcim, Lesser Poland Voivodeship, 32-600, Poland

  • Merz Investigative Site

    Lublin, Lublin Voivodeship, 20-607, Poland

  • Merz Investigative Site

    Warsaw, Masovian Voivodeship, 00-716, Poland

  • Merz Investigative Site

    Warsaw, Masovian Voivodeship, 01-142, Poland

  • Merz Investigative Site

    Warsaw, Masovian Voivodeship, 02-482, Poland

  • Merz Investigative Site

    Warsaw, Masovian Voivodeship, 02-953, Poland

  • Merz Investigative Site

    Bialystok, Podlaskie Voivodeship, 15-453, Poland

  • Merz Investigative Site

    Gdynia, Pomeranian Voivodeship, 81-537, Poland

  • Merz Investigative Site

    Warsaw, 02-962, Poland

  • Merz Investigative Site

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Merz Investigative Site

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 27-400, Poland

  • Merz Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Merz Investigative Site

    Valencia, 46010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.